[go: up one dir, main page]

EA201070163A1 - Цитотоксические средства, включающие новые производные томаймицина, и их терапевтическое применение - Google Patents

Цитотоксические средства, включающие новые производные томаймицина, и их терапевтическое применение

Info

Publication number
EA201070163A1
EA201070163A1 EA201070163A EA201070163A EA201070163A1 EA 201070163 A1 EA201070163 A1 EA 201070163A1 EA 201070163 A EA201070163 A EA 201070163A EA 201070163 A EA201070163 A EA 201070163A EA 201070163 A1 EA201070163 A1 EA 201070163A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
tomaymic
therapeutic application
including new
tomaimycin
Prior art date
Application number
EA201070163A
Other languages
English (en)
Other versions
EA019938B1 (ru
Inventor
Эрве Бушар
Рави В. Дж. Чари
Ален Коммерсон
Юнхун Дэн
Лоранс Гози
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39048765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201070163(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Publication of EA201070163A1 publication Critical patent/EA201070163A1/ru
Publication of EA019938B1 publication Critical patent/EA019938B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Изобретение относится к новым производным томаймицина, содержащим линкер. Изобретение также относится к конъюгатным молекулам, которые содержат одно или более указанных производных томаймицина, ковалентно связанных с агентом, связывающимся с клеткой, посредством сшивающей группы, присутствующей на линкере производного соединения томаймицина. Изобретение также относится к получению производных соединений томаймицина и конъюгатных молекул.
EA201070163A 2007-07-19 2008-07-18 Цитотоксические средства, включающие новые соединения томаймицина, и их терапевтическое применение EA019938B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290904.7A EP2019104B1 (en) 2007-07-19 2007-07-19 Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
PCT/IB2008/002869 WO2009016516A2 (en) 2007-07-19 2008-07-18 Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use

Publications (2)

Publication Number Publication Date
EA201070163A1 true EA201070163A1 (ru) 2010-08-30
EA019938B1 EA019938B1 (ru) 2014-07-30

Family

ID=39048765

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070163A EA019938B1 (ru) 2007-07-19 2008-07-18 Цитотоксические средства, включающие новые соединения томаймицина, и их терапевтическое применение

Country Status (39)

Country Link
US (1) US8404678B2 (ru)
EP (2) EP2019104B1 (ru)
JP (1) JP5551070B2 (ru)
KR (1) KR101627871B1 (ru)
CN (1) CN101784550B (ru)
AR (1) AR067575A1 (ru)
AT (1) ATE530553T1 (ru)
AU (1) AU2008281439B2 (ru)
BR (1) BRPI0814267A2 (ru)
CA (1) CA2693551C (ru)
CL (1) CL2008002139A1 (ru)
CO (1) CO6290692A2 (ru)
CR (1) CR11225A (ru)
CY (2) CY1112278T1 (ru)
DK (2) DK2019104T3 (ru)
DO (1) DOP2010000014A (ru)
EA (1) EA019938B1 (ru)
EC (1) ECSP109875A (ru)
ES (2) ES2435779T3 (ru)
GT (1) GT201000008A (ru)
HR (1) HRP20120067T1 (ru)
IL (1) IL203318A (ru)
JO (1) JO2744B1 (ru)
MA (1) MA31617B1 (ru)
ME (1) ME00969B (ru)
MY (1) MY151245A (ru)
NI (1) NI201000005A (ru)
NZ (1) NZ582679A (ru)
PA (1) PA8790201A1 (ru)
PE (2) PE20130590A1 (ru)
PL (2) PL2019104T3 (ru)
PT (2) PT2019104E (ru)
RS (1) RS52245B (ru)
SI (2) SI2019104T1 (ru)
TN (1) TN2010000002A1 (ru)
TW (1) TWI500618B (ru)
UA (1) UA98153C2 (ru)
WO (1) WO2009016516A2 (ru)
ZA (1) ZA201000389B (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2621035C2 (ru) * 2011-02-15 2017-05-31 Иммуноджен, Инк. Способы получения конъюгатов
US11505617B2 (en) 2009-02-05 2022-11-22 Immunogen, Inc. Benzodiazepine derivatives

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3826769A1 (de) 1988-08-06 1990-02-15 Bayer Ag Behandlung von polyamidfasern
EP2399609B1 (en) 2005-08-24 2015-03-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
KR20100033419A (ko) 2007-07-19 2010-03-29 메타볼렉스, 인코포레이티드 당뇨병 및 대사 장애의 치료를 위한 rup3 또는 gpr119 수용체의 작용제로서 n-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체
DE102008056086A1 (de) * 2008-11-06 2010-05-12 Gp Solar Gmbh Additiv für alkalische Ätzlösungen, insbesondere für Texturätzlösungen sowie Verfahren zu dessen Herstellung
AU2015224492B2 (en) * 2009-02-05 2017-04-20 Immunogen, Inc. Novel benzodiazepine derivatives
RU2595424C2 (ru) 2009-06-03 2016-08-27 Иммьюноджен, Инк. Способы конъюгации
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) * 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
EP2483281B1 (en) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
CN102971329B (zh) 2010-04-15 2016-06-29 麦迪穆有限责任公司 用于治疗增殖性疾病的吡咯并苯并二氮杂卓
PT2528625E (pt) * 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
KR101772354B1 (ko) 2010-04-15 2017-08-28 시애틀 지네틱스, 인크. 표적화된 피롤로벤조디아제핀 접합체
BR112012032248A2 (pt) 2010-06-23 2016-09-13 Metabolex Inc composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
KR102103302B1 (ko) 2011-03-29 2020-04-23 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
WO2012145112A2 (en) * 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker
CA2849039C (en) 2011-09-20 2018-09-18 Spirogen Sarl Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates
JP6399930B2 (ja) 2011-10-14 2018-10-03 シアトル ジェネティクス,インコーポレーテッド ピロロベンゾジアゼピンおよび標的コンジュゲート
EA027386B1 (ru) 2011-10-14 2017-07-31 Медимьюн Лимитед Пирролобензодиазепины
WO2013053873A1 (en) 2011-10-14 2013-04-18 Spirogen Sàrl Pyrrolobenzodiazepines
ES2945932T3 (es) 2011-10-14 2023-07-10 Seagen Inc Pirrolobenzodiazepinas y conjugados dirigidos
CA2859444A1 (en) * 2011-12-13 2013-06-20 Immunogen, Inc. Use of n-hydroxysuccinimide to improve conjugate stability
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
AR090903A1 (es) 2012-05-01 2014-12-17 Genentech Inc Anticuerpos e inmunoconjugados anti-pmel17
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
AR091703A1 (es) 2012-07-09 2015-02-25 Genentech Inc Anticuerpos e inmunoconjugados que comprenden anticuerpos anti-cd22
HK1209042A1 (en) 2012-07-09 2016-03-24 基因泰克公司 Immunoconjugates comprising anti-cd79b antibodies
EP2879708A4 (en) 2012-08-02 2016-03-16 Genentech Inc ANTIBODY AND ANTI-ETBR IMMUNOCONJUGATES
EP2887965A1 (en) 2012-08-22 2015-07-01 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
EP2904089A4 (en) * 2012-10-04 2016-05-25 Immunogen Inc USE OF A PVDF MEMBRANE FOR PURIFYING CELL BINDING AGENT-CYTOTOXIC AGENT CONJUGATES
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
ES2703151T3 (es) 2012-10-12 2019-03-07 Adc Therapeutics Sa Conjugados de anticuerpos de pirrolobenzodiazepinas
HUE052835T2 (hu) 2012-10-12 2021-05-28 Medimmune Ltd Pirrolobenzodiazepinek és konjugátumaik
US10751346B2 (en) 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
CN109134599A (zh) 2012-10-12 2019-01-04 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
SI2906296T1 (en) 2012-10-12 2018-06-29 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
CA2885305C (en) 2012-10-12 2019-11-12 Spirogen Sarl Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
ES2701076T3 (es) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
MX364330B (es) 2013-03-13 2019-04-23 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
MX363787B (es) * 2013-03-13 2019-04-03 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de los mismos.
PL2968494T3 (pl) 2013-03-13 2019-04-30 Seattle Genetics Inc Filtracja z węglem aktywnym do oczyszczania benzodiazepinowych ADC
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US10150813B2 (en) 2013-03-14 2018-12-11 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US10442836B2 (en) 2013-08-12 2019-10-15 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015042108A1 (en) 2013-09-17 2015-03-26 Genentech, Inc. Methods of using anti-lgr5 antibodies
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
TW201533060A (zh) 2013-12-13 2015-09-01 Genentech Inc 抗cd33抗體及免疫結合物
CN105828840B (zh) 2013-12-16 2020-08-04 基因泰克公司 1-(氯甲基)-2,3-二氢-1H-苯并[e]吲哚二聚体抗体-药物缀合物化合物及使用和治疗方法
CA2938919C (en) 2014-02-28 2020-12-29 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
CN106414499A (zh) 2014-05-22 2017-02-15 基因泰克公司 抗gpc3抗体和免疫偶联物
EP3186284B1 (en) 2014-08-28 2022-04-06 BioAtla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
US9381256B2 (en) 2014-09-03 2016-07-05 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
KR102632830B1 (ko) 2014-09-03 2024-02-02 이뮤노젠 아이엔씨 세포독성 벤조다이아제핀 유도체
MX2017003022A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados.
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
SG10201809668TA (en) 2014-09-12 2018-11-29 Genentech Inc Anti-her2 antibodies and immunoconjugates
AR101848A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos de anti-b7-h4 e inmunoconjugados
BR112017004953A2 (pt) * 2014-09-17 2017-12-05 Genentech Inc imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
US10780096B2 (en) * 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
ES2747386T3 (es) 2015-01-14 2020-03-10 Bristol Myers Squibb Co Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso
BR112017014599A2 (pt) 2015-01-14 2018-01-16 Bristol-Myers Squibb Company dímeros de benzodiazepina, conjugados dos mesmos, e métodos de preparação e uso
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
KR20180019592A (ko) 2015-06-23 2018-02-26 브리스톨-마이어스 스큅 컴퍼니 마크로시클릭 벤조디아제핀 이량체, 그의 접합체, 제조법 및 용도
CN108449940B (zh) 2015-07-12 2021-06-08 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CN113004288A (zh) 2015-07-21 2021-06-22 伊缪诺金公司 制备细胞毒性苯并二氮杂䓬衍生物的方法
EP4477269A3 (en) 2015-09-20 2025-03-19 The United States of America, as Represented By the Secretary, Department of Health and Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
WO2017107817A1 (zh) * 2015-12-21 2017-06-29 江苏恒瑞医药股份有限公司 一种抗体药物偶联物的制备方法
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
JP6735355B2 (ja) 2016-04-15 2020-08-05 バイオアトラ、エルエルシー 抗Axl抗体、抗体断片およびそれらの免疫コンジュゲートならびにそれらの使用
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
PT3455261T (pt) 2016-05-13 2022-11-11 Bioatla Llc Anticorpos anti-ror2, fragmentos de anticorpo, seus imunoconjugados e suas utilizações
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
CN107469089B (zh) * 2016-06-07 2022-01-07 北京键凯科技股份有限公司 一种peg连接子及配基药物偶联物
US11066479B2 (en) 2016-08-02 2021-07-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
JP2019527693A (ja) 2016-08-03 2019-10-03 サイマベイ・セラピューティクス・インコーポレイテッドCymaBay Therapeutics,Inc. 炎症性胃腸疾患または胃腸状態を治療するためのオキシメチレンアリール化合物
CN109689111B (zh) 2016-08-11 2024-04-05 基因泰克公司 吡咯并苯并二氮杂䓬前药及其抗体缀合物
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2018086139A1 (en) 2016-11-14 2018-05-17 Hangzhou Dac Biotech Co., Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
KR102477612B1 (ko) 2016-11-21 2022-12-14 쿠레아브 게엠베하 항-gp73 항체 및 면역접합체
CA3044391A1 (en) 2016-11-23 2018-05-31 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
CA3045902A1 (en) 2016-12-21 2018-06-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for flt3 and uses thereof
PL3558391T3 (pl) 2016-12-23 2022-05-16 Immunogen, Inc. Immunokoniugaty skierowane wobec białka adam9 i sposoby ich stosowania
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
HRP20210979T1 (hr) 2017-02-08 2021-09-17 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protutijelo
AU2018255876B2 (en) 2017-04-18 2020-04-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
MX2019012464A (es) 2017-04-20 2019-12-11 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
TW201839001A (zh) 2017-04-20 2018-11-01 美商伊繆諾金公司 細胞毒性苯并二氮平衍生物及其綴合物
CA3059472A1 (en) 2017-05-19 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
UA127900C2 (uk) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Схема дозування для введення adc до cd19
WO2019006280A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
HRP20220311T1 (hr) 2017-08-18 2022-05-13 Medimmune Limited Konjugati pirolobenzodiazepina
EP3690038A4 (en) 2017-09-29 2021-05-19 Daiichi Sankyo Company, Limited ANTIBODY PYRROLOBENZODIACEPINE DERIVATIVE CONJUGATE
TWI827575B (zh) 2017-12-28 2024-01-01 美商伊繆諾金公司 苯二氮平衍生物
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US11939377B2 (en) 2018-07-12 2024-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured CD22-specific monoclonal antibody and uses thereof
CN112585163B (zh) 2018-08-08 2025-03-25 美国政府(由卫生和人类服务部的部长所代表) 靶向磷脂酰肌醇蛋白聚糖-2的高亲和力单克隆抗体及其用途
TW202029980A (zh) 2018-10-26 2020-08-16 美商免疫遺傳股份有限公司 E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途
IL319265A (en) 2018-12-21 2025-04-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and their uses
JP7542266B2 (ja) * 2019-01-03 2024-08-30 リガケム バイオサイエンシズ, インク. 安定性が向上したピロロベンゾジアゼピン二量体化合物及びその用途
CN113490510B (zh) 2019-01-08 2025-02-14 美国政府(由卫生和人类服务部的部长所代表) 用于治疗实体瘤的靶向间皮素的跨物种单结构域抗体
CA3125033A1 (en) 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
JP2022523333A (ja) 2019-01-30 2022-04-22 トゥルーバインディング,インコーポレイテッド 抗gal3抗体およびその使用
KR20210139270A (ko) 2019-03-15 2021-11-22 메드임뮨 리미티드 암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트
KR20220010481A (ko) 2019-03-29 2022-01-25 이뮤노젠 아이엔씨 비정상 세포 성장의 억제 또는 증식성 질환의 치료를 위한 세포독성 비스-벤조디아제핀 유도체 및 세포결합제와 이의 접합체
AU2020370125A1 (en) 2019-10-22 2022-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting B7H3 (CD276) for treating multiple solid tumors
JP7679380B2 (ja) 2019-12-12 2025-05-19 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ Cd276に特異的な抗体-薬物コンジュゲートおよびその使用
MX2022011499A (es) 2020-03-19 2022-10-07 Avidity Biosciences Inc Composiciones y metodos para tratar la distrofia muscular facioescapulohumeral.
IL296393A (en) 2020-03-27 2022-11-01 Avidity Biosciences Inc Preparations and methods for the treatment of muscle atrophy
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング,インコーポレイテッド ガレクチン-3を遮断することにより炎症性疾患を処置する方法
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
CN117500831A (zh) 2021-06-09 2024-02-02 美国政府(由卫生和人类服务部的部长所代表) 用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体
WO2023288252A1 (en) 2021-07-13 2023-01-19 Truebinding, Inc. Methods of preventing protein aggregation
EP4401792A1 (en) 2021-09-16 2024-07-24 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
AU2022388722A1 (en) 2021-11-09 2024-05-23 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases
IL316223A (en) 2022-05-03 2024-12-01 Genentech Inc Anti-LY6E antibodies, immunoconjugates and their uses
WO2025019228A1 (en) 2023-07-20 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516743A (fr) 1966-04-01 1968-02-05 Rhone Poulenc Sa Nouvel antibiotique et son procédé de préparation par culture de streptomyces croceus
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE69231123T2 (de) 1992-03-25 2001-02-15 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
PT1109812E (pt) 1998-08-27 2005-09-30 Spirogen Ltd Pirrolobenzodiazepinas
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
NZ517772A (en) 1999-11-24 2004-03-26 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
EA010570B1 (ru) 2002-11-07 2008-10-30 Иммьюноджен, Инк. Антитело к cd33 и способы его применения
ATE413407T1 (de) * 2003-03-31 2008-11-15 Council Scient Ind Res Pyrrolo(2,1-c)(1,4)benzodiazepin-dimere als antitumormittel und verfahren dafür
WO2004091542A2 (en) 2003-04-15 2004-10-28 Covx Pharmaceuticals, Inc. Nitrogen containing integrin targeting compounds
EP1660513B9 (en) 2003-07-21 2012-04-04 ImmunoGen, Inc. A ca6 antigen-specific cytotoxic conjugate and methods of using the same
GB0321295D0 (en) * 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
AU2004284075A1 (en) * 2003-10-22 2005-05-06 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
GB0404577D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
GB0404578D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
US7528126B2 (en) 2004-03-09 2009-05-05 Spirogen Limited Pyrrolobenzodiazepines
GB0410725D0 (en) * 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
PL1813614T3 (pl) * 2006-01-25 2012-03-30 Sanofi Sa Środki cytotoksyczne zawierające nowe pochodne tomaymycyny
WO2008010101A2 (en) * 2006-07-18 2008-01-24 Sanofi-Aventis Antagonist antibody against epha2 for the treatment of cancer
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11505617B2 (en) 2009-02-05 2022-11-22 Immunogen, Inc. Benzodiazepine derivatives
RU2621035C2 (ru) * 2011-02-15 2017-05-31 Иммуноджен, Инк. Способы получения конъюгатов
RU2631498C2 (ru) * 2011-02-15 2017-09-25 Иммуноджен, Инк. Цитотоксические производные бензодиазепина
USRE49918E1 (en) 2011-02-15 2024-04-16 Immunogen, Inc. Cytotoxic benzodiazepine derivatives

Also Published As

Publication number Publication date
SI2170890T1 (sl) 2012-02-29
CY1112278T1 (el) 2015-12-09
EP2170890B1 (en) 2011-10-26
EP2019104A1 (en) 2009-01-28
NI201000005A (es) 2010-03-09
HRP20120067T1 (hr) 2012-02-29
PA8790201A1 (es) 2009-02-09
TWI500618B (zh) 2015-09-21
CR11225A (es) 2010-06-23
ATE530553T1 (de) 2011-11-15
CN101784550B (zh) 2014-06-11
TN2010000002A1 (en) 2011-09-26
MA31617B1 (fr) 2010-08-02
CY1114922T1 (el) 2016-12-14
CO6290692A2 (es) 2011-06-20
UA98153C2 (ru) 2012-04-25
EA019938B1 (ru) 2014-07-30
WO2009016516A3 (en) 2009-06-11
PT2170890E (pt) 2012-02-03
CL2008002139A1 (es) 2009-10-23
PL2019104T3 (pl) 2014-03-31
US8404678B2 (en) 2013-03-26
CA2693551A1 (en) 2009-02-05
PT2019104E (pt) 2013-12-03
TW200922598A (en) 2009-06-01
PL2170890T3 (pl) 2012-04-30
CN101784550A (zh) 2010-07-21
ECSP109875A (es) 2010-02-26
ES2435779T3 (es) 2013-12-23
GT201000008A (es) 2012-03-26
BRPI0814267A2 (pt) 2015-03-31
HK1144289A1 (en) 2011-02-11
IL203318A (en) 2016-08-31
DK2019104T3 (da) 2013-12-16
JP2010533703A (ja) 2010-10-28
NZ582679A (en) 2012-04-27
JP5551070B2 (ja) 2014-07-16
DK2170890T3 (da) 2012-02-27
ME00969B (me) 2012-06-20
CA2693551C (en) 2016-09-20
US20100316656A1 (en) 2010-12-16
WO2009016516A8 (en) 2009-04-16
ZA201000389B (en) 2011-04-28
KR20100063021A (ko) 2010-06-10
SI2019104T1 (sl) 2013-12-31
MY151245A (en) 2014-04-30
ES2376026T3 (es) 2012-03-08
EP2170890A2 (en) 2010-04-07
WO2009016516A2 (en) 2009-02-05
DOP2010000014A (es) 2010-02-15
PE20130590A1 (es) 2013-05-22
AR067575A1 (es) 2009-10-14
AU2008281439A1 (en) 2009-02-05
KR101627871B1 (ko) 2016-06-07
RS52245B (en) 2012-10-31
PE20090889A1 (es) 2009-08-06
JO2744B1 (en) 2014-03-15
EP2019104B1 (en) 2013-09-04
AU2008281439B2 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
EA201070163A1 (ru) Цитотоксические средства, включающие новые производные томаймицина, и их терапевтическое применение
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
BRPI0915084B8 (pt) composto, e, composição farmacêutica
EA200900048A1 (ru) Новые карбонилированные (аза)циклогексаны в качестве лигандов d3 рецептора дофамина
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
Baraldi et al. Hybrid molecules between distamycin A and active moieties of antitumor agents
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA201792652A3 (ru) Новые производные майтанзиноида с пептидным линкером и их конъюгаты
EA201991268A3 (ru) Получение конъюгатов "майтансиноид-антитело" одностадийным способом
ECSP088871A (es) Derivados de triazolopirazina
BR112016002829A2 (pt) Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
BRPI0910746B8 (pt) agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
EA201170772A1 (ru) Органические соединения
BRPI0607240A2 (pt) derivados de maleimida, composições farmacêuticas e métodos para tratamento de cáncer
MY151986A (en) Adamantyl diamide derivatives and uses of same
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
UY29370A1 (es) Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones
EA201070804A1 (ru) (аза)индольное производное, замещенное по положению 5, содержащая его фармацевтическая композиция, промежуточные соединения и способ их получения
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
WO2010089327A3 (en) Indole derivatives as anticancer agents
BRPI0620985B1 (pt) composição farmacêutica, e usos de derivados de triazina e sensibilizadores de insulina

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU